Background: The primary endpoint of head-to-head comparisons of coronary drugeluting stents is traditionally assessed after 9-12 months. However, the optimal time point for assessment of the primary endpoint remains unsettled. Methods: We randomised 2,332 patients to zotarolimus-eluting EndeavorÔ stent (E-ZES; n¼1,162) or sirolimus-eluting CypherÔ stent (C-SES; n¼1,170) implantation. Endpoints included a composite of cardiac death, myocardial infarction or target vessel revascularization (MACE) and definite stent thrombosis. This trial is registered with ClinicalTrials.gov, number NCT00660478. Results: At 5-year follow-up, MACE rates were similar in patients treated with E-ZES and C-SES (197 [17%] In the E-ZES and C-SES group, 26 of 88 (30%) and 54 of 70 (77%) of target lesion revascularisations occurred between 1 and 5 years, respectively. Conclusions: A traditional 1-year primary endpoint is insufficient to predict 5-year clinical outcome in patients treated with coronary drug-eluting stent implantation. Long-term clinical data from routine clinical care populations should be a prerequisite for unrestricted use of new coronary drug-eluting stents.
Background: The primary endpoint of head-to-head comparisons of coronary drugeluting stents is traditionally assessed after 9-12 months. However, the optimal time point for assessment of the primary endpoint remains unsettled. Methods: We randomised 2,332 patients to zotarolimus-eluting EndeavorÔ stent (E-ZES; n¼1,162) or sirolimus-eluting CypherÔ stent (C-SES; n¼1,170) implantation. Endpoints included a composite of cardiac death, myocardial infarction or target vessel revascularization (MACE) and definite stent thrombosis. This trial is registered with ClinicalTrials.gov, number NCT00660478. Results: At 5-year follow-up, MACE rates were similar in patients treated with E-ZES and C-SES (197 [17%] Background: Longterm results with drug eluting stents are important considering late differences in stent thrombosis, neo-athererosclerosis and catch-up phenomena that has been observed in several stent studies. Furthermore, little is known of longterm results with the everolimus-eluting stent, specifically in comparison with the paclitaxel-eluting stent. Methods: 1800 consecutive patients scheduled for PCI have been randomized to receive a Xience VÒ (EES) or Taxus LiberteÒ (PES) stent. Inclusion criteria were: patients eligible for PCI and a life expectancy of > 5 years. Major exclusion criteria were: no expected dual platelet therapy for 12 months, cardiac shock at presentation, planned major surgery within 1 month. The primary end point is the composite of: all death, non fatal myocardial infarction (MI) and target vessel revascularization (TVR) at 12 months. The secondary end points are: A) The combined endpoint of cardiac death, MI, ischemic driven target lesion revascularization rate at 12 months follow-up. B) the combined endpoint of all death, MI and TVR rate at 3 and 5 years follow-up. All patients will be monitored up to 60 months follow-up. Adjudication of events and core lab analysis of unscheduled angios is done independently by Cardialysis, Rotterdam, The Netherlands. A post-hoc SYNTAX score analysis will be done in the subgroup of multivessel and/or left main treatment. Results: No differences in patient baseline characteristics and lesion characteristics were present between both groups. Clinical presentation was similar in both groups (EES versus PES: Stable angina 40 vs 41%, Unstable angina 12 vs 12%, Non STEMI 22 vs 24%, STEMI 27 vs 23%, respectively). Overall 1.4 lesions per patient have been treated with an average of 1.6 stents per lesion and an average 2.3 stents per patient, reflecting real world situation with pronounced vessel disease patients. The adjudication of events between 3 and 5 year follow-up is in progress and will be ready first week September 2013.
Conclusions: COMPARE is the first trial that will show adjudicated longterm data of EES and in comparison to PES. These 5 year results may have clinical implications, specifically for those patients with high SYNTAX scores. Instituto Dante Pazzanese, Sao Paulo, Sao Paulo Background: US guidelines currently recommend 12 months of uninterrupted DAPT after implantation of DES. Prolonged and more powerful DAPT regimens have offered benefit by reducing VLST, but at the cost of increased risk of bleeding. There is an emerging need for new stents that are less dependent on prolonged DAPT. The BioFreedomÔ stent (BFD) releases Biolimus A9Ô, without using a polymer or binder. Based on an animal model, 98% of the drug diffuses to the vessel wall within 1 month, leaving a BMS in place. It is reasonable therefore to consider that the stent offers a potential safety advantage and a reduced need for prolonged DAPT compared to a polymer based DES. This First-In-Man trial aims to demonstrate the safety and effectiveness of the BFD compared to the Taxus LibertéÔ paclitaxel-eluting stent (PES). Methods: The BioFreedom FIM is a prospective, multi-center, randomized trial. 182 patients were enrolled and randomized to BFD Standard Dose (SD, 15.6 mg/mm), or BFD Low Dose (LD, 7.8 mg/mm), or Taxus .57] compared to PES (p sup¼0.11) at 12 months. At 3 years, the clinical FU was 96%. The BFD SD and PES showed similar rates of MACE (BFD SD 11.9% vs. PES 10.0%) with no definite/probable ST in any group. Interestingly, at 2 years, there was a significant difference in adherence to DAPT between the groups (BFD SD 5.2% vs. PES 19% p¼0.025) which disappeared at 3 years. Conclusions: The safety and efficacy of the polymer free BioFreedom has been shown out to 3 years. An ongoing trial is studying the possibility of using this stent in patients with high bleeding risk, unable to tolerate a prolonged course of DAPT. The BioFreedom FIM 4-year follow-up will be reported for the 1st time during this presentation.
